57 related articles for article (PubMed ID: 37612638)
1. Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools.
Feng X; Wu WY; Onwuka JU; Haider Z; Alcala K; Smith-Byrne K; Zahed H; Guida F; Wang R; Bassett JK; Stevens V; Wang Y; Weinstein S; Freedman ND; Chen C; Tinker L; Nøst TH; Koh WP; Muller D; Colorado-Yohar SM; Tumino R; Hung RJ; Amos CI; Lin X; Zhang X; Arslan AA; Sánchez MJ; Sørgjerd EP; Severi G; Hveem K; Brennan P; Langhammer A; Milne RL; Yuan JM; Melin B; Johansson M; Robbins HA; Johansson M
J Natl Cancer Inst; 2023 Sep; 115(9):1050-1059. PubMed ID: 37260165
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutation status: emerging biomarker for precision radiation medicine?
Willers H; Wang M; Benes CH
Oncoscience; 2018 Sep; 5(9-10):258-259. PubMed ID: 30460326
[No Abstract] [Full Text] [Related]
3. TP53 Mutations Emerge as a Critical Biomarker in Penile Cancer, Superseding Human Papillomavirus Status.
Chahoud J; Yu X; Necchi A; Spiess PE
Eur Urol; 2024 May; ():. PubMed ID: 38749849
[No Abstract] [Full Text] [Related]
4. TP53 mutations in nonsmall cell lung cancer.
Mogi A; Kuwano H
J Biomed Biotechnol; 2011; 2011():583929. PubMed ID: 21331359
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation prevalence in normal airway epithelium as a biomarker for lung cancer risk.
Craig DJ; Crawford EL; Chen H; Grogan EL; Deppen SA; Morrison T; Antic SL; Massion PP; Willey JC
BMC Cancer; 2023 Aug; 23(1):783. PubMed ID: 37612638
[TBL] [Abstract][Full Text] [Related]
6. Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
Craig DJ; Morrison T; Khuder SA; Crawford EL; Wu L; Xu J; Blomquist TM; Willey JC
BMC Cancer; 2019 Nov; 19(1):1081. PubMed ID: 31711466
[TBL] [Abstract][Full Text] [Related]
7. A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells.
Yeo J; Crawford EL; Zhang X; Khuder S; Chen T; Levin A; Blomquist TM; Willey JC
BMC Cancer; 2017 May; 17(1):301. PubMed ID: 28464886
[TBL] [Abstract][Full Text] [Related]
8. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
9. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
10. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
11. Clinical validation and utility of Percepta GSC for the evaluation of lung cancer.
Mazzone P; Dotson T; Wahidi MM; Bernstein M; Lee HJ; Feller Kopman D; Yarmus L; Whitney D; Stevenson C; Qu J; Johnson M; Walsh PS; Huang J; Lofaro LR; Bhorade SM; Kennedy GC; Spira A; Rivera MP; ;
PLoS One; 2022; 17(7):e0268567. PubMed ID: 35830375
[TBL] [Abstract][Full Text] [Related]
12. Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA.
Willey JC; Morrison TB; Austermiller B; Crawford EL; Craig DJ; Blomquist TM; Jones WD; Wali A; Lococo JS; Haseley N; Richmond TA; Novoradovskaya N; Kusko R; Chen G; Li QZ; Johann DJ; Deveson IW; Mercer TR; Wu L; Xu J
Cell Rep Methods; 2021 Nov; 1(7):100106. PubMed ID: 35475002
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Patient With a Pulmonary Nodule: A Review.
Mazzone PJ; Lam L
JAMA; 2022 Jan; 327(3):264-273. PubMed ID: 35040882
[TBL] [Abstract][Full Text] [Related]
14. Integrated Biomarkers for the Management of Indeterminate Pulmonary Nodules.
Kammer MN; Lakhani DA; Balar AB; Antic SL; Kussrow AK; Webster RL; Mahapatra S; Barad U; Shah C; Atwater T; Diergaarde B; Qian J; Kaizer A; New M; Hirsch E; Feser WJ; Strong J; Rioth M; Miller YE; Balagurunathan Y; Rowe DJ; Helmey S; Chen SC; Bauza J; Deppen SA; Sandler K; Maldonado F; Spira A; Billatos E; Schabath MB; Gillies RJ; Wilson DO; Walker RC; Landman B; Chen H; Grogan EL; Barón AE; Bornhop DJ; Massion PP
Am J Respir Crit Care Med; 2021 Dec; 204(11):1306-1316. PubMed ID: 34464235
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
